|
Accueil > Actualité
Phaxiam: listing suspended pending a press release
(CercleFinance.com) - Phaxiam Therapeutics announced on Thursday that it had requested the suspension of trading of its shares on the Paris stock exchange, pending the publication of a press release.
At a strategic briefing at the end of January, the biopharmaceutical company announced that it had joined forces with another well-known European player in the phage field, with the aim of accelerating the deployment of individualized phage-based treatments, a prospect which could generate sales as early as 2026. With cash and cash equivalents reaching 3.6 million euros at the end of 2024, Phaxiam had nevertheless declared that it was 'actively' seeking funds to extend its financial horizon beyond March 2025. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
09/05/2025 16:44
Infineona reçu une approbation pour l'usine de Dresde 09/05/2025 16:27 Alphabetléger rebond à l'issue d'une semaine difficile 09/05/2025 16:07 Lonzabien orienté après un point trimestriel 09/05/2025 15:49 Infineonaccord avec Visteon pour les véhicules électriques 09/05/2025 15:35 J&Jdonnées de phase 3 positives dans le psoriasis 09/05/2025 15:13 Vodafoneprochain changement de son directeur financier Tous les articles sociétés |
